Table 1 Patient characteristics.
nccRCC group (n = 21) | cc-RCC group (n = 165) | p | |
|---|---|---|---|
Age (year, median, IQR) | 60.0 (55.0–73.0) | 67.0 (58.0–72.0) | 0.568 |
Sex (number, %) | |||
Male | 13 (61.9) | 125 (75.8) | 0.271 |
Female | 8 (38.1) | 40 (24.2) | |
IMDC risk classification (number, %) | |||
Favorable risk | 1 (4.8) | 17 (10.3) | 0.717 |
Intermediate risk | 14 (66.7) | 102 (61.8) | |
Poor risk | 6 (28.6) | 46 (27.9) | |
Histological type (number, %) | |||
Clear cell | 0 | 165 (100) | |
Papillary | 15 (71.4) | 0 | |
Chromophobe | 2 (9.5) | 0 | |
Acuired cystic disease-associated | 2 (9.5) | 0 | |
MiT family translocation | 1 (4.8) | 0 | |
Fumarate hydratase deficient | 1 (4.8) | 0 | |
Sarcomatoid feature (number, %) | 3 (14.3) | 16 (9.8) | 0.793 |
Fuhrman grade (Number, %) | |||
1 | 0 | 14 (8.5) | |
2 | 2 (9.5) | 52 (31.5) | |
3 | 10 (47.6) | 34 (20.6) | |
4 | 3 (14.3) | 19 (11.5) | |
Unknown | 6 (28.6) | 46 (27.9) | |
Number of metastatic sites (number, %) | |||
0 | 1 (4.7) | 15 (9.1) | 0.918 |
1 | 9 (42.9) | 73 (44.2) | |
≥ 2 | 11 (52.4) | 77 (46.7) | |
The metastatic sites (number, %) | |||
Lymph node | 9 (42.9) | 49 (29.7) | 0.329 |
Lung | 10 (47.6) | 109 (66.1) | 0.157 |
Bone | 5 (23.8) | 53 (32.1) | 0.600 |
Liver | 6 (28.6) | 16 (9.7) | 0.030 |
Brain | 1 (4.8) | 12 (7.3) | > 0.999 |
The number of patients performed with nephrectomy before treatment (number, %) | 15 (71.4) | 88 (53.3) | 0.181 |
The number of patients with deferred cytoreductive nephrectomy (number, %) | 3 (14.3) | 10 (6.1) | 0.348 |
Follow-up period (year, median, IQR) | 17.7 (4.4–24.8) | 20.4 (9.9–35.0) | 0.108 |
